Skip to main content

Table 4 Responses for ‘knowledge needed’ (N (%) responses) for all responses that relate to knowledge needed)

From: Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada

Nodes Sub-nodes Sub-sub-node e-learning module (N = 188) Site visits (N = 85) Barriers & Facilitators Survey (N = 65)
Mechanism of action 11 (5.9 %) 2 (2.4 %) 17 (26.2 %)
 Administration Overall 47 (25.0 %) 61 (71.8 %) 26 (40.0 %)
 Transfer 0 2 0
 Threatened preterm labour vs. imminent preterm birth 3 10 0
 Timing of administration 6 9 7
 Standards of practice 4 10 2
 Re-treatment 0 7 3
 Pre-printed orders 1 0 0
 Policies and protocols 8 3 7
 Multiple pregnancies 1 0 0
 Gestational age 8 7 2
 Drug interactions 5 0 0
 Contraindications 1 2 0
 Unclassified 10 11 5
 Side effects and risks Overall 26 (13.8 %) 16 (18.8 %) 6 (9.2 %)
 Rapid delivery 1 0 0
 Overuse 1 1 0
 Interventions as a result of MgSO4 3 0 0
 Increased monitoring needed 5 0 0
 Adverse physiological effects – neonate  Toxicity 3 1 0
   Problems with feeding 1 0 0
   Neonatal respiratory depression 6 3 0
   Long-term effects 0 1 2
   Adverse neurological effects 1 0 0
 Adverse physiological effects – general (unspecified maternal/neonate) 0 7 0
 Unclassified 4 2 4
 KT tools Overall 7 (3.7 %) 0 3 (4.6 %)
 Audit and feedback 1 0 0
 Unclassified 6 0 3
 Research Overall 46 (24.5 %) 5 (5.9 %) 13 (20.0 %)
 Further research 33 3 5
 Evidence to date 6 1 7
 Unclassifiable 7 1 1
 Other uses and topics (not MgSO4 for fetal neuroprotection) 30 (16.0 %) 1 (1.2 %) 0
 None stated 21 (11.2 %) 0 0
  1. MgSO4 (magnesium sulphate)
  2. Note that the total is broken down in various ways; each area until a bolded row adds to the total n listed in the bolded row